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ABSTRACT 
Background: Atherosclerosis is a chronic inflammatory disease, but data on arterial 
inflammation at early stages is limited.  
Objectives: To characterize vascular inflammation by hybrid 18F-fluorodeoxyglucose positron 
emission tomography/magnetic resonance imaging (18F-FDG PET/MRI).  
Methods: Carotid, aortic, and ilio-femoral 18F-FDG PET/MRI was performed in 755 individuals 
(age 40-54 years, 83.7% men) with known plaques detected by 2D/3D vascular ultrasound 
and/or coronary calcification in the PESA (Progression of Early Subclinical Atherosclerosis) 
study. We evaluated the presence, distribution, and number of arterial inflammatory foci 
(increased 18F-FDG uptake) and plaques with or without inflammation (coincident 18F-FDG 
uptake).  
Results: Arterial inflammation was present in 48.2% of individuals (24.4% femorals, 19.3% 
aorta, 15.8% carotids, and 9.3% iliacs) and plaques in 90.1% (73.9% femorals, 55.8% iliacs, and 
53.1% carotids). 18F-FDG arterial uptakes and plaques significantly increased with 
cardiovascular risk factors (p<0.01). Coincident 18F-FDG uptakes were present in 287/2605 
(11%) plaques, and most uptakes were detected in plaque-free arterial segments (459/746; 
61.5%). Plaque burden, defined by plaque presence, number, and volume, was significantly 
higher in individuals with arterial inflammation than in those without (p<0.01). The number of 
plaques and 18F-FDG uptakes showed a positive albeit weak correlation (r=0.25; p<0.001). 
Conclusion: Arterial inflammation is highly prevalent in middle-aged individuals with known 
subclinical atherosclerosis. Large-scale multiterritorial PET/MRI allows characterization of 
atherosclerosis-related arterial inflammation and demonstrates 18F-FDG uptake in plaque-free 
arterial segments and, less frequently, within plaques. These findings suggest an arterial 
inflammatory state at early stages of atherosclerosis. 
Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT01410318. 
 
CONDENSED ABSTRACT 
Data on arterial inflammation in early atherosclerosis is limited. We characterized vascular 
inflammation by carotid, aortic, and ilio-femoral hybrid 18F- FDG PET/MRI in 755 individuals 
(age 40-54 years, 83.7% men) with subclinical atherosclerosis in the PESA study. Arterial 
inflammation was present in 48.2% of individuals, most commonly at the femoral territory. Most 
uptakes (61.5%) were detected in plaque-free arterial segments, and only 11% of plaques showed 
coincident uptake. Thus, arterial inflammation detected by multiterritorial PET/MRI is highly 
prevalent in middle-aged individuals with subclinical atherosclerosis, both in plaque-free arterial 
segments and, less frequently, within plaques, suggesting an active arterial inflammatory state. 
 
KEY WORDS: 18F-FDG PET/MRI, subclinical atherosclerosis, arterial inflammation, plaque 
inflammation 
 
ABBREVIATIONS LIST:  
CT: Computed tomography 
18F-FDG: 18F-Fluorodeoxyglucose 
MRI: Magnetic resonance imaging 
PET: Positron emission tomography 
SUV: Standardized uptake value 
TBR: Target-to-background ratio  
Introduction 
Atherosclerosis is a chronic disease in which inflammation plays an important role at all 
stages, from development and progression to the determination of incident clinical events (1-3). 
Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) can assess arterial 
inflammation in vivo because uptake reflects, at least in part, the presence of invading 
macrophages and foam cell formation (4). Prior studies combining PET and computed 
tomography (CT) have shown that arterial 18F-FDG uptake predicts cardiovascular risk, although 
these studies were largely limited to a single vascular territory and/or included individuals 
retrospectively screened for cancer (5-8). Magnetic resonance imaging (MRI) can provide 
superior plaque detection and characterization, and thus hybrid 18F-FDG PET-MRI technology 
has the potential to simultaneously provide anatomical and functional information (9). However, 
data on vascular PET/MRI is scarce, with only small series limited to carotid atherosclerosis (10-
12). 
Our aim was to characterize arterial and plaque inflammation associated with early 
atherosclerosis by performing multiterritorial hybrid 18F-FDG PET/MRI in a large prospective 
asymptomatic cohort of middle-aged individuals with subclinical atherosclerosis. We also 
evaluated patient- and plaque-specific factors associated with inflammation.  
Methods 
Study population 
This study was conducted in a subset of participants with known subclinical 
atherosclerosis from the Progression of Early Subclinical Atherosclerosis (PESA)-CNIC-
Santander study (13). PESA is an observational, prospective cohort study of 4184 asymptomatic 
employees of the Santander Bank in Madrid. Participants were aged 40-54 years at enrollment 
and were consecutively recruited between June 2010 and February 2014, with visits at baseline 
and at 3 and 6 years. Exclusion criteria were prior cardiovascular disease, any condition reducing 
life expectancy or affecting study adherence, morbid disease (body mass index ≥40 kg/m2), or 
chronic kidney disease (estimated glomerular filtration rate (eGFR) <60 mL/min/m2). The main 
objective is to characterize the presence and progression of subclinical atherosclerosis by non-
invasive imaging, including carotid and ilio-femoral vascular ultrasound and non-contrast 
cardiac CT. A subgroup of participants with documented atherosclerosis, defined as being in the 
highest plaque thickness tertile on vascular ultrasound and/or having any coronary artery 
calcification on CT, were offered a vascular 18F-FDG PET/MRI study during the baseline visit. 
Cardiovascular risk factors were prospectively assessed at enrollment and defined as (14) : 1) 
diabetes: fasting plasma glucose ≥126 mg/dL, or treatment with insulin or oral hypoglycemic 
medication; 2) arterial hypertension: systolic blood pressure ≥140 mmHg, diastolic blood 
pressure ≥90 mmHg, or use of antihypertensive medication; 3) dyslipidemia: total cholesterol 
≥240 mg/dL, low-density lipoprotein cholesterol ≥160 mg/dL, high-density lipoprotein 
cholesterol <40 mg/dL, or use of lipid-lowering drugs; 4) smoking: current smoking status, and a 
lifetime consumption of >100 cigarettes; 5) family history of cardiovascular disease: first degree-
relative diagnosed with atherosclerosis before the age of 55 years in men and 65 in women; 6) 
obesity: body mass index ≥30 kg/m2. Cardiovascular risk was evaluated by the 10-year risk 
algorithm based on Pooled Cohort Equations (15), and cut-off values were defined as <5%, 5 to 
<7.5% and ≥7.5 risk for low, intermediate, and high risk, respectively (15). The eGFR was 
calculated according to the Chronic Kidney Disease Epidemiology equation (16). High 
sensitivity C-reactive protein (hs-CRP) was measured in venous blood collected after fasting 
(13). The institutional Ethics Committee approved the study protocol and all participants 
provided written informed consent.  
Hybrid PET/MRI 
Acquisition protocol  
Pre-scan preparation requirements included fasting for 6 hours and refraining from 
exercise in the preceding 24 hours. Plasma glucose levels were measured before the scan (mean 
concentration 90.6 ± 12.3 mg/dL). Participants received a target dose of 270-300 MBq 18F-FDG 
(17) and were asked to remain at rest in a quiet room for 30 minutes after radiolabel injection. 
The associated radiation exposure was calculated according to the ICRP Task Group on 
Radiation Dose (18). Sequential whole-body PET/MRI studies were performed in a Philips 
Ingenuity TF PET/MR hybrid system (Philips Healthcare, Cleveland, OH). MRI was performed 
with a phased-array 16-channel torso XL coil for aorto-iliac and femoral arteries and a 16-
channel neurovascular coil for carotid arteries, using peripheral pulse gating. 
The imaging protocol is illustrated in Figure 1, and detailed MRI parameters are shown in 
Online Table 1. The protocol included high-resolution black-blood MRI of the carotid, iliac, and 
femoral arteries and co-registered PET/MRI of the carotid arteries, thoracic aorta, infrarenal 
abdominal aorta, iliac, and femoral arteries. Ilio-femoral MRI attenuation maps and lower-body 
PET were acquired at the start of the protocol. After standard localizers, iliac arteries (15 cm 
covering up to the aorto-iliac bifurcation) and femoral arteries (6 cm centered at the bifurcation) 
were first scanned using an axial double-inversion black-blood fast spin-echo T1-weighted 
sequence with spectral fat suppression. When plaques were visualized, additional T2-weighted 
images (typically 3 slices) were obtained of the largest plaque in a territory. Afterwards, an axial 
stack of balanced single-shot fat-saturated turbo-field echo images of the infrarenal aorta and 
ilio-femoral arteries was acquired for subsequent coregistered PET/MRI analysis. Finally, a 
specific MRI sequence for attenuation correction was obtained with the body coil. The table was 
then removed from the MRI scanner and rotated 180° into the PET system (at least 90 min after 
18F-FDG injection). A PET scan of the infrarenal abdominal aorta and ilio-femoral territories was 
acquired in the cranio-caudal direction in 4 bed positions (3 minutes per bed) with 50% overlap, 
covering from the umbilicus to the upper portion of the leg. After a 5-minute rest off the table, 
the participant returned to the MRI platform for surveys and attenuation sequences of the carotid 
and thoracic aortic territories. This was followed by table rotation and a cranio-caudal upper-
body PET in 5 bed positions (3 minutes per bed) with 50% overlap, covering from the external 
auditory meatus to the diaphragm (at least 120 min after 18F-FDG injection). Participants were 
then returned to the MRI scanner, and axial balanced single-shot turbo-field echo imaging was 
performed of the carotid arteries and thoracic aorta, followed by carotid T1-black-blood 
weighted imaging (6 cm centered at the bifurcation) and selective plaque T2-weighted imaging 
as above.  
Image reconstruction and analysis 
PET scans were reconstructed in 3-dimensional mode using a blob-based, list-mode 
iterative algorithm with time-of-flight (TOF) information and corrections applied for attenuation, 
scatter, and random coincidences. Attenuation correction used MRI attenuation maps with a 3-
class tissue (soft tissue, lung, and air) validated segmentation technique (19). A transverse 576-
mm field of view was used and images were generated with a voxel size of 4.0 x 4.0 x 4.0 mm3. 
Specific templates for PET images were added to the attenuation maps to correct for attenuation 
effects of the scanner bed and the neurovascular coil. Similarly, truncation correction was used to 
compensate for the limited field of view from MRI images (20).  
All images were obtained and reviewed by expert technologists, radiologists, or nuclear 
medicine specialists blinded to previous imaging procedures and clinical data. MRI data were 
analyzed with VP Diagnostics software (Seattle, USA) and PET/MRI data were analyzed with 
Philips Fusion Viewer V2.0. A total of 6 vascular territories per participant were analyzed in 
MRI: left/right carotid arteries (common and internal, excluding external), left/right iliac arteries 
(aorto-iliac bifurcation and common and external, excluding internal), and left/right femoral 
arteries (common and superficial, excluding deep). In each territory, the presence and number of 
plaques (1, 2, >2) was recorded as a surrogate of plaque burden. Atherosclerotic plaques were 
defined as focal luminal protrusions of the wall ≥1.5mm in radial thickness on T1-weighted 
images, according to previous reported methodology (21) and the best discrimative cut-off 
within our population, using ultrasound as a reference (n=100; area under the curve 
[AUC]=0.80). On T1-weighted images, the inner and outer wall contours were manually traced 
in all sections containing plaque as well as in a proximal reference slice. Positive remodeling was 
defined as the ratio of maximal vessel area at the level of the plaque to the proximal reference 
vessel area ≥1.1 (22).  We also traced plaque contours in each diseased slice to quantify plaque 
volume. Plaques were defined as predominantly lipid-rich if iso/hyperintense on T1- and 
hypointense on T2-weighted images, predominantly fibrous if iso/hyperintense on both (23), or 
mixed/indeterminate if combined features were present or the plaque was too small to be 
defined; however, analyzers were encouraged to assign plaques predominantly to the first two 
categories.  
A total of 10 vascular territories per participant were analyzed on fused PET/MRI images, 
including the left/right carotid arteries, ascending/arch/descending thoracic aorta, infrarenal 
abdominal aorta, left/right iliac arteries, and left/right femoral arteries. Qualitative PET analysis 
on each vessel was performed after adjustment of the color scale between 0 and 2 standardized 
uptake value (SUV) units. In each studied territory the presence and number (1, 2, >2) of arterial 
18F-FDG uptakes was recorded (inflammatory burden). An arterial 18F-FDG uptake was defined 
as a localized area of increased signal intensity encompassing an artery and that could not be 
explained by adjacent structures such as lymph nodes or urethers (24,25). On every slice 
demonstrating arterial uptake, regions of interest encompassing wall and lumen were drawn to 
quantify maximal SUV (SUVmax, calculated as decay-corrected tissue radioactivity divided by 
body weight and injected dose) and target-to-background ratio (TBRmax, calculated as the ratio 
of SUVmax to background venous activity) (26). Venous activity was measured as mean SUV in 
the ipsilateral jugular veins for carotid studies, superior vena cava for the thoracic aorta, or 
inferior vena cava for the abdominal aorta and ilio-femoral arteries. We also assessed whether 
plaques visualized on T1-weighted MRI showed coincident 18F-FDG uptake (plaque with 
inflammation) for the 6 territories with both PET and high-resolution T1-weighted MRI images 
(left/right carotid arteries, left/right iliac arteries, and left/right femoral arteries) and measured 
SUVmax and TBRmax per plaque. For plaques without coincident uptake (plaques without 
inflammation), we assigned the mean SUVmax and TBRmax values of the corresponding vessel 
in the absence of concomitant uptakes, or otherwise the contralateral vessel. 
Statistical Analysis 
Continuous variables are expressed as mean ± standard deviation (or median 
[interquartile range] if non-normally distributed) and categorical variables as n (%). Non-normal 
variables were log-transformed before analysis and comparisons were performed using the 
Student t-test and the Chi-square or Fisher exact test, as appropriate. To examine the bivariate 
relationships between continuous variables, we used the Spearman rank correlation with 95% 
confidence intervals based on the Fisher transformation. For multivariate analysis, logistic 
regression models were performed. For plaque analyses, multilevel mixed models were applied 
to account for within-subject correlation. To evaluate arterial inflammation associations, the 
model was adjusted for age, sex, hypertension, smoking, diabetes, dyslipidemia, obesity, and 
family history of cardiovascular disease; to evaluate plaque inflammation, adjustments were 
made for bifurcation location, plaque volume, carotid or femoral distribution, positive 
remodeling, and lipid-rich or fibrotic content. Odds ratios and 95% confidence intervals are 
reported. For all endpoints, p values <0.05 were considered statistically significant. Statistical 
analyses were performed using STATA 15.0. 
For reproducibility analysis, PET/MRI images of 15 participants (150 PET and 90 MRI 
vascular territories) were independently analyzed in a random manner by two expert PET and 
MRI readers. One of the readers re-analyzed the same studies after a minimum interval of 1 
month. Interobserver and intraobserver agreement was assessed by intraclass correlation 
coefficient (ICC), with 95% confidence intervals for continuous measurements and Kappa Cohen 
coefficients for categorical variables. Agreement was defined as good if ICC=0.71-0.90 or 
Kappa=0.61-0.8, and excellent if ICC>0.90 or Kappa=0.81-1 (27,28). Reproducibility 
measurements were good and excellent for all endpoints (Online Table 2). 
Results 
In PESA, we performed PET/MRI in 946 participants (78.8% of invitees) who had 
documented atherosclerosis detected on baseline vascular ultrasound or CT: peripheral plaques 
in 349 (36.9%), coronary calcification in 69 (7.3%), and both in 523 (55.3%). Mean 18F-FDG 
dose was 292.3 ± 11.1 MBq, and radiation exposure was 5.6 ± 0.2 mSv. Mean start time after 
18F-FDG injection was 106.0 ± 15.0 min for lower-body PET and 132.9 ± 19.9 min for upper-
body PET. Reasons for non-completion are shown in Online Figure 1, mainly due to physicial 
intolerance in upper-body studies (8 PETs and 51 MRIs), technical issues with the MRI 
attenuation maps (97 initial PETs), and poor image quality (70 iliac MRIs). Thus, complete 
PET/MRI studies were available in 755 (79.8%) participants.  
The mean age of the PET/MRI cohort was 49.6 ± 4.3 years, 632 (83.7%) were men, and 
all individuals were Caucasians. The most prevalent risk factor wasdyslipidemia, followed by 
smoking, family history, obesity, hypertension, and diabetes (Table 1). Most participants had low 
cardiovascular risk (62.0%, versus 18.0% with intermediate risk and 20.0% with high risk). The 
prevalence of statin therapy in the complete PET/MRI cohort was 13.9%, with no significant 
differences between individuals with or without inflammation. hs-CRP was significantly 
elevated in individuals with arterial inflammation (Table 1) and positively but weakly correlated 
with arterial/plaque uptakes and plaque presence, volume, and composition (Online Table 3) A 
total of 2605 atherosclerotic plaques were detected by MRI in 680 participants (90.1%; 3 [2-5] 
plaques per participant), being more frequent in men. Plaque number increased with age and the 
presence of cardiovascular risk factors (Figure 2, Online Figures 2 and 3).  
Arterial inflammation and plaque inflammation in atherosclerotic PESA participants 
Arterial inflammation, defined as increased vascular 18F-FDG uptake, was present in 364 
participants (48.2%; total uptakes 746, 2 [1-2] per participant). The femoral territory was the 
most frequent location for both inflammation and plaque (Central Illustration). Figure 3 shows 
the prevalence of plaques and inflammation according to sex and vascular territories. Participants 
with arterial inflammation were older and had more cardiovascular risk factors than participants 
without arterial inflammation. Similarly, arterial uptake number increased with age and 
cardiovascular risk factors, both globally and in most arterial territories (Figure 2, Online 
Figures 2 and 3). Individuals with arterial uptakes also had increased plaque burden, as 
demonstrated by plaque presence, number, and volume (Table 1). There was a modest 
correlation between the number of plaques and the number of arterial uptakes (r=0.25; 95% 
confidence intervals 0.19-0.32; p<0.001). Most uptakes (459/746; 61.5%) were detected in 
plaque-free arterial segments. In multivariate analysis, arterial inflammation was independently 
associated with age, male sex, smoking, and obesity (Figure 4, left). 
Plaque inflammation, defined as coincident 18F-FDG uptake in plaques, was detected in 
196 participants (26.0%). Plaques with and without inflammation are compared in Table 2. Only 
11% of plaques showed coincident uptake (287 vs 2318 without inflammation out of 2605 total 
plaques). Compared with plaques without inflammation, plaques with inflammation were located 
more frequently in the femoral territory and in bifurcations, demonstrated more positive 
remodeling, were larger, and more frequently had a lipid-rich composition. Also, plaques with 
inflammation had higher SUVmax and TBRmax values than plaques without inflammation 
(p<0.001). In multivariate analysis, plaque features that significantly predicted uptake were 
location (carotid or femoral vs iliac) and larger volume (Figure 4, right). The predominant 
features of plaques with and without inflammation are illustrated in Figure 5. 
Similar results for arterial inflammation and plaque inflammation were obtained in a 
further multivariate analysis excluding participants taking statins (Online Table 4). 
DISCUSSION 
Vascular inflammation is a central component of atherosclerosis as supported by 
extensive experimental evidence, human observational data, and the recent demonstration of the 
potential beneficial effects of anti-inflammatory therapies in advanced atherothrombotic disease 
(29). Imaging early arterial inflammation in vivo can therefore help understand the pathogenesis 
and natural history of atherosclerosis (30). Retrospective studies, mostly performed in 
individuals screened for cancer, suggest that arterial inflammation (as detected by 18F-FDG 
PET/CT) is common and heralds future events (5,6); nonetheless, prospective human data on its 
prevalence is limited to small series (31) and typically to single vascular territories (10). 
In this PESA cohort, by far the largest ever reported using hybrid PET/MRI of multiple 
vascular territories, 18F-FDG PET/MRI prospectively detected arterial inflammation in almost 
50% of middle-aged, asymptomatic, predominantly low-risk individuals with subclinical 
atherosclerosis. These data are comparable to those from a previous retrospective study of PET 
for cancer screening, in which half of the individuals aged 41 to 60 years demonstrated vascular 
18F-FDG uptake (8). We found arterial inflammation to be most prevalent in the femoral 
territory, which may be related to the higher atherosclerotic burden in this territory, a site of early 
atherosclerosis involvement as previously demonstrated (14). To our knowledge, only one 
retrospective PET study, in cancer patients, has described a more frequent vascular uptake in the 
femoral arteries, followed by the iliac and carotid territories (8). Tahara et al (32) reported a 
prevalence of carotid inflammation in 29% of patients with documented carotid atherosclerosis, 
similar to the 24% with carotid plaques found in our cohort. In another cancer cohort (24), 16% 
of patients had thoracic aortic 18F-FDG uptake, also comparable to our study. In agreement with 
a previous report (33), hs-CRP levels in the PESA cohort were elevated in individuals with 
arterial inflammation. These findings support the existence of a pro-inflammatory state in early 
atherosclerosis. Our PET/MRI data were obtained in accordance with recommended standards 
for 18F-FDG circulation time and radiation exposure (26,34), showing good reproducibility 
comparable to previous publications (35,36). This opens the possibility of large-scale in vivo 
imaging of systemic atherosclerosis-related inflammation, its study in early disease stages, and 
the identification of patients likely to benefit from early intervention. 
In PESA, arterial inflammation increased according to the cardiovascular risk profile and 
was independently associated with male sex, age, smoking, and obesity. Our findings validate 
previous preliminary studies in small samples that suggested these associations (33,37). The 
predictive role of male sex for any 18F-FDG uptake could be related to the smaller number of 
women in the cohort, but may also reflect the anti-inflammatory effects of female hormones (eg, 
estrogen), which can attenuate arterial inflammatory responses (38). In our cohort, although the 
mean age of women was 48.4 ± 4.1 years, most (74.8%) were premenopausal and thus exposed 
to the potential protective effects of estrogens. The link in our study between smoking and 
increased arterial 18F-FDG uptake is in line with published findings showing that smoking 
promotes immune-mediated vascular injury and accelerated atherosclerosis and is also associated 
with increased levels of inflammatory markers and PET activity detected with specific 
radiotracers (39,40). Our findings on obesity are also consistent with extensive literature showing 
a pro-inflammatory effect of body fat due to the release by adipocytes of proinflammatory 
cytokines, which play a central role in vascular inflammation (41,42).  
Interestingly, inflammation was present in only 11% of plaques with most uptakes 
detected in plaque-free arterial walls. We found that the numbers of 18F-FDG uptakes and 
plaques were positively correlated; however, the correlation was weak, as they frequently did not 
coincide. This finding suggests that uptakes and plaques represents different pathophysiological 
or temporal phenomena in atherosclerosis (43).  Regarding factors related to plaque 
inflammation using PET/MRI, Hyafil et al (11) found an association between high-risk plaques 
and inflammation in 18 patients with ischemic stroke and non-stenotic lesions. Our study, for the 
first time, shows strong evidence of a plaque phenotype associated with 18F-FDG uptake using 
hybrid PET/MRI technology, based on almost 3000 plaques distributed across multiple territories 
and including near 300 plaques with coincident inflammation. Plaques with 18F-FDG uptake 
were more commonly located in bifurcations,lipid-rich, and positively remodeled. However, in 
the multivariate analysis, only plaque volume and carotid or femoral (versus iliac) distribution 
were independent predictors of inflamed plaques. In agreement with our findings, histological 
evidence shows that highly inflamed plaques tend to be larger and have more positive 
remodeling and larger lipid cores (44). The reason for preferential uptake in the carotid and 
femoral territories compared with the iliac territory requires further investigation, but may be 
related to local wall shear stress conditions (45), different stages of atherosclerosis development 
in each vascular territory, and more physiological uptake in the abdominal organs, leading to 
potential pitfalls in imaging interpretation (46). In future studies, other factors related to focal 
inflammation might be identified by the inclusion of vascular territories that were unavailable in 
our MRI protocol, such as the aorta. In this sense, a recent study by Joshi et al demonstrated that 
increased aortic vascular inflammation detected by 18F-FDG PET/CT in 215 psoriasis patients is 
associated with early coronary artery disease independently of traditional cardiovascular risk 
factors (47). A previous small study (n=16) indicated preferential 18F-FDG uptake by lipid-rich 
plaques (31); however, we found that this association did not persist in the multivariate analysis. 
This apparent contradiction might be related to a more robust adjustment in our study for 
potential confounders. However, it should also be acknowledged that plaque characterization 
was available in approximately 50% of the detected plaques in PESA, and that the plaques were 
relatively small; therefore, our findings in this area should be taken with caution.  
Study limitations 
In line with recent data (43), our findings suggest that arterial inflammation may precede 
plaque formation; however, since this is a cross-sectional analysis, we cannot establish 
temporality or causation. Serial imaging in PESA, including an 18F-FDG PET/MRI study at 6-
year follow-up, will help to define the significance of these findings. Approximately 20% of 
individuals invited to participate declined enrollment or had MRI contraindications; however, 
this proportion is comparable to similar studies (48). The high success rate (nearly 80%) of our 
protocol may be influenced by the relatively young age and good health of the PESA 
participants, and tolerability would likely have been lower in older or frail patients. Nonetheless, 
we used a sequential PET/MRI system and newer integrated equipment can reduce examination 
times significantly (49). Almost the first 100 initial PETs could not be used due to inaccuracies 
in MRI-based attenuation and reconstruction, which likely reflects predictable challenges when 
introducing new technology, but feasibility was almost 100% thereafter. Although we attempted 
to evaluate arterial inflammation in as many territories as possible, some could not be evaluated, 
in particular the coronary arteries, which present specific technical challenges (50). High-
resolution black-blood MRI of the aorta was not performed in order to limit examination time; 
therefore, aortic plaques were not assessed. Another study limitation was the inclusion only of 
individuals with subclinical atherosclerosis, so that our findings may not be generalizable to 
populations without plaque; however, plaque-free vessels were evaluated. Experienced PET 
readers determined arterial and plaque uptake qualitatively, which is likely the way it would be 
used in clinical practice. In a post-hoc analysis (not shown), we calculated that the optimal 
SUVmax cutoff value for defining visually increased 18F-FDG plaque uptake was 1.5 
(AUC=0.86), in line with previous studies (32). Also, our analysis showed a positive correlation 
with hs-CRP, which to some extent provides an indirect validation of our method. However, the 
optimal quantitative approach to evaluate early atherosclerotic inflammation is not yet 
standardized, and detailed quantitative analyses in PESA are underway. Up to 13.9% of study 
participants were taking statin therapy, which could influence the results since statins exert anti-
inflammatory effects; however, a sensitivity analysis omitting these participants yielded similar 
results (Online Table 4).  
Conclusions 
Large-scale multiterritorial 18F-FDG PET/MRI identified arterial inflammation in 48% of 
middle-aged individuals with subclinical atherosclerosis, predominantly in the femoral territory. 
While inflammation extent correlated with plaque burden, inflammation uptakes and plaques 
frequently did not coincide, suggesting that they are distinct processes in atherogenesis. Age, 
male sex, obesity, and smoking independently predicted arterial inflammation. Inflammation was 
noted in only 11% of plaques and was predominantly associated with larger plaque volume and a 
femoral or carotid distribution. These findings demonstrate the potential for in vivo imaging of 
systemic atherosclerosis-related inflammation, its study at early stages, and the identification of 
individuals likely to benefit from early intervention. 
  
CLINICAL PERSPECTIVES 
Competency in Medical Knowledge: Arterial inflammation can be detected by 18F-FDG 
PET/MRI at multiple vascular sites in asymptomatic, middle-aged individuals with subclinical 
atherosclerosis, but these do not necessarily correspond to plaque. 
Translational Outlook: Future studies should investigate whether inflammation precedes plaque 
development and assess the value of quantifying inflammation in cardiovascular risk assessment. 
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Central Illustration. Inflammation by PET/MRI in Atherosclerosis. Prevalence of 
atherosclerosis and arterial inflammation by hybrid 18F-FDG PET/MRI across several vascular 
territories in the PESA participants. 18F-FDG PET/MRI: 18F-fluorodeoxyglucose positron 
emission tomography / magnetic resonance imaging. 
Figure 1. PESA study protocol for the assessment of multiterritorial atherosclerosis by 
hybrid positron emission tomography/ magnetic resonance imaging (PET/MRI). 18F-FDG: 
18F-fluorodeoxyglucose; T1w: T1-weighted; T2w: T2-weighted; SSh-TFE: Single shot turbo 
field echo. 
Figure 2. Relationship between 18F-FDG uptake and cardiovascular risk factor burden. 18F-
FDG: 18F-fluorodeoxyglucose; CVRF: cardiovascular risk factor. 0, 1, 2, or >2 CVRF in relation 
to diabetes, arterial hypertension, dyslipidemia, smoking, and a family history of cardiovascular 
disease or obesity, as defined in the main manuscript.  
Figure 3.  Prevalence of atherosclerosis and arterial inflammation in men and women in 
PESA. MRI: magnetic resonance imaging; PET: positron emission tomography.  
Figure 4. Multivariate logistic regression models for predicting arterial 18F-FDG uptake 
(arterial inflammation) and plaques with coincident 18F-FDG uptake (plaque 
inflammation). Left panels show patient-related factors associated with arterial inflammation, 
and right panels show plaque-related characteristics associated with inflammation. The models 
were adjusted for all variables shown in each part of the Figure. 
Figure 5. Typical phenotypic features of plaques with or without inflammation. Plaques 
with coincident 18F-FDG uptake are more prevalent in the femoral territory (at the bifurcation) 
and tend to be larger and have more positive remodeling and larger lipid cores (yellow); in 
contrast,plaques without coincident 18F-FDG uptake tend to be smaller, lack positive remodeling, 
and have a fibrotic composition (pink).  
  
Table 1. Characteristics of PESA study participants  
 
Values are mean ± standard deviation or median [interquartile range] for continuous variables or n (%) for 
categorical variables. P values relate to the comparison of the group with arterial inflammation versus the 













Age (years) 49.6 ± 4.3         50.3 ± 4.1 48.9 ± 4.4 <0.001 
Sex (male) 632 (83.7) 328 (90.1) 304 (77.7) <0.001 
10-year PCE risk 3.9 [2.2-6.5] 4.9 [3.0–7.7] 3.2 [1.6–5.4] <0.001 
Dyslipidemia 444 (58.8) 234 (64.3) 210 (53.7) 0.003 
Statin therapy 105 (13.9)            59 (16.2) 46 (11.8) 0.078 
Smoking* 201 (27.1) 112 (31.2) 89 (23.3) 0.016 
Obesity 147 (19.5) 100 (27.5) 47 (12.0) <0.001 
Hypertension 146 (19.3) 84 (23.1) 62 (15.9) 0.012 
Family history 155 (20.5) 76 (20.9) 79 (20.2) 0.819 
Diabetes 36 (4.8) 23 (6.3) 13 (3.3) 0.054 
eGFR (mL/min/m2) 100.5 [93.1-104.9]         100.7 [92.9-104.5] 100.2 [93.4-105.4] 0.403 
hs-CRP (mg/dL) 0.11 [0.06-0.21]         0.14 [0.08-0.27] 0.09 [0.05-0.17] <0.001 
MRI  
Presence of plaque 680 (90.1) 343 (94.2) 337 (86.2) <0.001 
Carotid 401 (53.1) 218 (59.9) 183 (46.8) <0.001 
Iliac 421 (55.8) 223 (61.3) 198 (50.6) 0.003 
Femoral 558 (73.9) 301 (82.7) 257 (65.7) <0.001 
Nº of plaques per participant 3 [2-5] 4 [2-5] 2 [1-4] <0.001 
Volume per plaque (mm3) 95.5 [48.9-173.8] 125.3 [70.8-243.7] 92.7 [46.7-164.9] <0.001 
high sensitivity C-reactive protein; PCE: pooled cohort equation; PET: positron emission tomography. 
*Smoking data are available for 741 individuals. 
  




Values are mean ± standard deviation or median [interquartile range] for continuous variables and n (%) 
for categorical variables. MRI: magnetic resonance imaging; SUV: standardized uptakes values; TBR: 
target-background ratio. *Positive arterial remodeling was calculated for 2552 plaques and SUV/TBRmax 
for 2284 plaques without uptake. †T2-weighted imaging was available for 1341 plaques (191 plaques with 
inflammation and 1150 plaques without inflammation). 
 
                                   
All plaques  
(n=2605)  
Plaques with 






Location     
Carotid 630 (24.2) 85 (29.6) 545 (23.5) 0.047 
Iliac 903 (34.7) 39 (13.6) 864 (37.3) <0.001 
Femoral  1,072 (41.2) 163 (56.8) 909 (39.2) <0.001 
Bifurcation 665 (25.5) 91 (31.7) 574 (24.8) 0.028 





189 (65.8) 1333 (57.5) 0.032 
Plaque composition†      
Lipid-rich  519 (38.7) 92 (48.2) 427 (37.1) 0.010 




9 (4.7) 64 (5.6) 0.717 
PET 
SUVmax per plaque  1.4 ± 0.3 1.7 ± 0.3 1.3 ± 0.3 <0.001 
TBRmax per plaque 1.6 ± 0.4 1.9 ± 0.5 1.6 ± 0.4 <0.001 
